Antifungal Activity and Safety of Caspofungin against Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits.

V. PETRAITIS1, R. PETRAITIENE1, A. KELAHER1, A. SARAFANDI1, T. SEIN1, R.L. SCHAUFELE1, A. FRANCESCONI1, J. BACHER2, T.J. WALSH1

Author address: 

1 NCI, NIH, Bethesda, MD, 2 OD, ORS, NIH, Bethesda, MD

Abstract: 

Background: In vitro studies demonstrate that caspofungin (CAS) has broad-spectrum activity against Candida species. The antifungal efficacy and safety of CAS were investigated in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits. Methods: Antifungal therapy groups consisted of CAS at 0.025 (CAS0.025), 0.1 (CAS0.1), 0.5 (CAS0.5), 1 (CAS1), fluconazole at 10 (FLU), amphotericin B at 1 (DAMB) mg/kg/day IV, or no drug (UC). Treatment started 24 h after the intravenous inoculation of 1x103 Candida albicans blastoconidia and continued for 12 days. Results: Rabbits treated with CAS0.025 (p
2002

abstract No: 

M-188

Full conference title: 

NULL
    • ICAAC 42nd